Early patient access to health technologies: Is innovation needed for early management?
- PMID: 32044105
- DOI: 10.1016/j.therap.2019.11.008
Early patient access to health technologies: Is innovation needed for early management?
Abstract
The question of early patient access to innovative health technologies arises from the assumption that, once a certain level of effectiveness or efficiency is achieved, waiting for mainstream coverage would represent a loss of opportunity for patients or for the community. This was the premise on which the round table based its dialogue. Early access is understood as the funding of a technology that comes within this field and is CE-marked but has not yet attained "mainstream" coverage. There are several early access schemes in France ("forfait innovation", early coverage, exceptional coverage, RIHN). This round table was an opportunity to establish mapping, extended to devices not dedicated to early access but which could nevertheless provide some patients with access to non-mainstreamed technologies (Article 51, ETAPES experiments, DGOS call for projects, local schemes). It is an initial step that would need to be further developed and complemented by the dissemination of common communication materials available to all, including patients. The existing schemes are in fact still poorly known. Consideration would also have to be given to the advisability of developing these schemes in order to adapt them to the new European requirements. More generally, early access schemes must be integrated into an ecosystem that is conducive for their relevance: consideration of procedures associated with medical devices benefiting from early access; short time frames of examination; patient information. Finally, the round table proposes the creation of a new early access scheme, complementary to those that exist and that would be positioned, after CE marking, between the "forfait innovation" and mainstreaming: PRESTO (Prise En charge Sécurisée et Temporaire de technologies innOvantes) (secure and temporary coverage for innovative technologies).
Keywords: Early access; Funding; Health technology; Innovation; Medical device; Technology assessment.
Copyright © 2019. Published by Elsevier Masson SAS.
Similar articles
-
French evaluation of innovative health technologies: Early access and fundings.Presse Med. 2025 Jun;54(2):104284. doi: 10.1016/j.lpm.2025.104284. Epub 2025 Apr 8. Presse Med. 2025. PMID: 40210188
-
Early access programs for medical devices in France: Overview of recent reforms and outcomes (2015-2022).Health Policy. 2024 Oct;148:105146. doi: 10.1016/j.healthpol.2024.105146. Epub 2024 Aug 11. Health Policy. 2024. PMID: 39154454
-
[Innovation funding schemes and the structuring of health economic evaluation in France].Therapie. 2024 May-Jun;79(3):327-339. doi: 10.1016/j.therap.2023.09.003. Epub 2023 Sep 22. Therapie. 2024. PMID: 37821312 Review. French.
-
Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.Health Policy. 2014 Jul;117(1):1-5. doi: 10.1016/j.healthpol.2014.04.007. Epub 2014 Apr 21. Health Policy. 2014. PMID: 24794738
-
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000. Pharmacoeconomics. 2010. PMID: 20085389 Review.
Cited by
-
International Market Access Strategies for Artificial Intelligence-Based Medical Devices: Can We Standardize the Process to Faster Patient Access?Mayo Clin Proc Digit Health. 2023 Aug 8;1(3):406-412. doi: 10.1016/j.mcpdig.2023.06.011. eCollection 2023 Sep. Mayo Clin Proc Digit Health. 2023. PMID: 40206615 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous